Insurance Impact on Outcomes for Rural Hematologic Patients | Kingsley Nnawuba, MD | ASH 2023

Insurance Impact on Outcomes for Rural Hematologic Patients | Kingsley Nnawuba, MD | ASH 2023
Real-World Safety and Efficacy of Teclistamab | Hamza Hashmi | ASH 2023
Efficacy of Reduced Dosing of Talquetamab in Relapsed Refractory Myeloma | Ajai Chari, MD | ASH 2023
Myeloma Treatment Comparison: RVd vs. D-RVd Outcomes | Nisha Joseph, MD | ASH 2023
Updated Safety and Efficacy Results of ABBV-383 | Ravi Vij, MD, MBA | ASH 2023
MGUS and Thrombotic Events: iStopMM Study Results | Sæmundur Rögnvaldsson, MD, PhD | ASH 2023